The finding that sparsentan prevented loss of endothelial glycocalyx and podocytes in gddY mice more effectively than losartan suggests a pivotal role of ET-1 and ETAR in these cells in IgAN in line with findings in other renal diseases. Here, EDNRA is linked to kidney disorder.